268 related articles for article (PubMed ID: 8176477)
21. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
22. Improved in vivo stability and tumor targeting of bismuth-labeled antibody.
Ruegg CL; Anderson-Berg WT; Brechbiel MW; Mirzadeh S; Gansow OA; Strand M
Cancer Res; 1990 Jul; 50(14):4221-6. PubMed ID: 2364380
[TBL] [Abstract][Full Text] [Related]
23. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies.
Roselli M; Schlom J; Gansow OA; Brechbiel MW; Mirzadeh S; Pippin CG; Milenic DE; Colcher D
Int J Rad Appl Instrum B; 1991; 18(4):389-94. PubMed ID: 1864727
[TBL] [Abstract][Full Text] [Related]
24. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
26. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
27. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
28. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
29. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
[TBL] [Abstract][Full Text] [Related]
30. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
[TBL] [Abstract][Full Text] [Related]
31. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
32. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice.
Sharkey RM; Motta-Hennessy C; Gansow OA; Brechbiel MW; Fand I; Griffiths GL; Jones AL; Goldenberg DM
Int J Cancer; 1990 Jul; 46(1):79-85. PubMed ID: 2114375
[TBL] [Abstract][Full Text] [Related]
33. The effect of chelating agents on the distribution of monoclonal antibodies in mice.
Ward MC; Roberts KR; Westwood JH; Coombes RC; McCready VR
J Nucl Med; 1986 Nov; 27(11):1746-50. PubMed ID: 3464701
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer.
Sabbah EN; Kadouche J; Ellison D; Finucane C; Decaudin D; Mather SJ
Nucl Med Biol; 2007 Apr; 34(3):293-304. PubMed ID: 17383579
[TBL] [Abstract][Full Text] [Related]
35. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
[TBL] [Abstract][Full Text] [Related]
37. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH
Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.
Chong HS; Milenic DE; Garmestani K; Brady ED; Arora H; Pfiester C; Brechbiel MW
Nucl Med Biol; 2006 May; 33(4):459-67. PubMed ID: 16720237
[TBL] [Abstract][Full Text] [Related]
39. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.
Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghans RP; Gansow OA; Waldmann TA
Cancer Res; 1989 May; 49(10):2639-44. PubMed ID: 2785435
[TBL] [Abstract][Full Text] [Related]
40. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
Kosmas C; Maraveyas A; Gooden CS; Snook D; Epenetos AA
J Nucl Med; 1995 May; 36(5):746-53. PubMed ID: 7738643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]